Faeth Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Faeth Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-225.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 90% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 3/3Sales grew in 0 of the last 3 years; profit grew in 3 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-14.1×Operating cash was negative last year, while some debt falls due within a year.
Higher than 51% of Healthcare companies in United States.
Cash Cushion Ratio
+4%Cash, after subtracting all debt, equals 4% of its market value (net cash).
Lower than 60% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Faeth Therapeutics, Inc. made a loss over the last year. Faeth Therapeutics, Inc. owes $0.09 for every $1 it owns. Faeth Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossFaeth Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.00The share price is 3.00 times Faeth Therapeutics, Inc.'s book value per share, higher than 55% of Healthcare companies in United States.
Market cap
$519 MThe total market value of all of Faeth Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 55% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$173 MWhat Faeth Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$6.69Net worth divided by the number of shares. The share price of $20.10 is 3.0 times this, which is the P/B above.
Return on equity (ROE)
-195.3%Faeth Therapeutics, Inc. lost 195.3% of its shareholders' money over the last year, lower than 84% of Healthcare companies in United States.
Owes vs Owns
0.09×Faeth Therapeutics, Inc. owes $0.09 for every $1 it owns (low), lower than 89% of Healthcare companies in United States.
Dividend yield
NoneFaeth Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossFaeth Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredFaeth Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashFaeth Therapeutics, Inc. held $20 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Faeth Therapeutics, Inc.: $519 M ÷ $173 M (30 Jun 2026) = 3.0.
What is Faeth Therapeutics, Inc.'s return on equity?
Faeth Therapeutics, Inc. lost 195.3% of its shareholders' money over the last year, lower than 84% of Healthcare companies in United States.
How much does Faeth Therapeutics, Inc. owe compared with what it owns?
Faeth Therapeutics, Inc. owes $0.09 for every $1 it owns (low), lower than 89% of Healthcare companies in United States.
Does Faeth Therapeutics, Inc. pay a dividend?
No. Faeth Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.